137 related articles for article (PubMed ID: 24648996)
1. Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells.
Otsuka T; Hamada A; Iguchi K; Usui S; Hirano K
Biomed Rep; 2013 Jul; 1(4):614-618. PubMed ID: 24648996
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells.
Iguchi K; Ito M; Usui S; Mizokami A; Namiki M; Hirano K
J Androl; 2008; 29(2):207-12. PubMed ID: 17916567
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein 3: an androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells.
Juang HH; Chung LC; Sung HC; Feng TH; Lee YH; Chang PL; Tsui KH
Prostate; 2013 Oct; 73(14):1495-506. PubMed ID: 23794209
[TBL] [Abstract][Full Text] [Related]
5. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
[TBL] [Abstract][Full Text] [Related]
6. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
7. Zinc and metallothionein levels and expression of zinc transporters in androgen-independent subline of LNCaP cells.
Iguchi K; Otsuka T; Usui S; Ishii K; Onishi T; Sugimura Y; Hirano K
J Androl; 2004; 25(1):154-61. PubMed ID: 14662799
[TBL] [Abstract][Full Text] [Related]
8. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.
Lee C; Sutkowski DM; Sensibar JA; Zelner D; Kim I; Amsel I; Shaw N; Prins GS; Kozlowski JM
Endocrinology; 1995 Feb; 136(2):796-803. PubMed ID: 7530653
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
11. Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells.
Robbins SE; Shu WP; Kirschenbaum A; Levine AC; Miniati DN; Liu BC
Prostate; 1996 Dec; 29(6):362-70. PubMed ID: 8977633
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of sex hormone-binding globulin on androgen-induced proliferation and androgen metabolism in LNCaP prostate cells.
Damassa DA; Lin TM; Sonnenschein C; Soto AM
Endocrinology; 1991 Jul; 129(1):75-84. PubMed ID: 2055206
[TBL] [Abstract][Full Text] [Related]
13. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line.
Kirschenbaum A; Ren M; Levine AC
Steroids; 1993 Sep; 58(9):439-44. PubMed ID: 8236330
[TBL] [Abstract][Full Text] [Related]
14. Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.
Harada S; Keller ET; Fujimoto N; Koshida K; Namiki M; Matsumoto T; Mizokami A
Prostate; 2001 Mar; 46(4):319-26. PubMed ID: 11241555
[TBL] [Abstract][Full Text] [Related]
15. Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
Fiandalo MV; Wilton JH; Mantione KM; Wrzosek C; Attwood KM; Wu Y; Mohler JL
Prostate; 2018 Feb; 78(3):213-221. PubMed ID: 29194687
[TBL] [Abstract][Full Text] [Related]
16. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
17. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
Kim HJ; Park YI; Dong MS
Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
[TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
20. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
